Clinical trial
Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and…
NCT00424762 · University of Texas Southwestern Medical Center, Other · Completed
Key facts
| NCT number | NCT00424762 |
|---|---|
| Title | Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride |
| Official title | Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride |
| Lead sponsor | University of Texas Southwestern Medical Center, Other |
| Collaborators | GlaxoSmithKline Industry Abbott RDx Cardiometabolic |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | rosiglitazone, placebo |
| Enrollment | 150 |
| Start date | Feb 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Jan 22, 2007 |
| Last update posted | Apr 4, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: